Page last updated: 2024-12-05

tetraphenylborate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Tetraphenylborate, also known as sodium tetraphenylborate or NaBPh4, is a white, crystalline solid with the formula Na[B(C6H5)4]. It is a common reagent in chemistry, used for precipitation and analysis. It is synthesized by the reaction of phenylmagnesium bromide with boron trifluoride etherate, followed by treatment with sodium hydroxide. Tetraphenylborate is a large anion, which makes it useful for precipitating large cations, such as potassium, rubidium, and cesium. It is also used in analytical chemistry for the determination of these cations. Tetraphenylborate is also used as a catalyst in organic synthesis, and as an additive in plastics and rubbers. It is studied for its use in various applications due to its unique properties, such as its large size, its ability to form stable complexes, and its reactivity with a variety of compounds.'

Tetraphenylborate: An anionic compound that is used as a reagent for determination of potassium, ammonium, rubidium, and cesium ions. It also uncouples oxidative phosphorylation and forms complexes with biological materials, and is used in biological assays. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID8934
CHEMBL ID587884
MeSH IDM0021249

Synonyms (23)

Synonym
AKOS005439462
svhqoiwiruvwii-uhfffaoysa-
inchi=1/c24h20b/c1-5-13-21(14-6-1)25(22-15-7-2-8-16-22,23-17-9-3-10-18-23)24-19-11-4-12-20-24/h1-20h/q-1
STK331798
tetraphenylborate(1-)
tetraphenylborate
tetraphenylboranuide
CHEMBL587884
gnf-pf-5539 ,
4358-26-3
unii-8tyc18k6nx
borate(1-), tetraphenyl-
8tyc18k6nx ,
SVHQOIWIRUVWII-UHFFFAOYSA-N
bdbm37044
tetraphenylboranuide;n,n,3-trimethylimidazol-3-ium-1-sulfonamide
tetraphenylboranuide;n,n,3-trimethyl-1-imidazol-3-iumsulfonamide
cid_3237940
tetra(phenyl)borate
Q2016367
STARBLD0016692
163709-59-9
DTXSID801336454

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" The orally bioavailable lead imidazolopiperazine confers complete causal prophylactic protection (15 milligrams/kilogram) in rodent models of malaria and shows potent in vivo blood-stage therapeutic activity."( Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.
Barnes, SW; Bonamy, GM; Bopp, SE; Borboa, R; Bright, AT; Chatterjee, A; Che, J; Cohen, S; Dharia, NV; Diagana, TT; Fidock, DA; Froissard, P; Gagaring, K; Gettayacamin, M; Glynne, RJ; Gordon, P; Groessl, T; Kato, N; Kuhen, KL; Lee, MC; Mazier, D; McNamara, CW; Meister, S; Nagle, A; Nam, TG; Plouffe, DM; Richmond, W; Roland, J; Rottmann, M; Sattabongkot, J; Schultz, PG; Tuntland, T; Walker, JR; Winzeler, EA; Wu, T; Zhou, B; Zhou, Y, 2011
)
0.37

Dosage Studied

ExcerptRelevanceReference
" The assay of amodiaquine hydrochloride in pharmaceutical dosage forms using one of the proposed sensors gave average recoveries of 104."( Amodiaquine polymeric membrane electrode.
Amighi, K; Blankert, B; Kambu, O; Kauffmann, JM; Malongo, TK; Nsangu, J, 2006
)
0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID449706NOVARTIS: Inhibition Frequency Index (IFI) - the number of HTS assays where a compound showed > 50% inhibition/induction, expressed as a percentage of the number of assays in which the compound was tested.2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID449704NOVARTIS: Inhibition of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID449705NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7)2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID449703NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay 2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID602156Novartis GNF Liver Stage Dataset: Malariabox Annotation2011Science (New York, N.Y.), Dec-09, Volume: 334, Issue:6061
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (260)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990121 (46.54)18.7374
1990's52 (20.00)18.2507
2000's43 (16.54)29.6817
2010's38 (14.62)24.3611
2020's6 (2.31)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 45.38

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index45.38 (24.57)
Research Supply Index5.62 (2.92)
Research Growth Index4.37 (4.65)
Search Engine Demand Index70.86 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (45.38)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (0.36%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other274 (99.64%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]